Multi-layer Blown Films
The research report includes specific segments by region (country), by manufacturers, by Type and ... Read More
1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Neurological Disorder Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Antipsychotic 1.2.3 Hypnotic & Sedative 1.2.4 Analgesics 1.2.5 Anticoagulants 1.2.6 Others 1.3 Market by Application 1.3.1 Global Neurological Disorder Drugs Market Share by Application: 2017 VS 2021 VS 2028 1.3.2 Hospital 1.3.3 Clinic 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Neurological Disorder Drugs Market Perspective (2017-2028) 2.2 Neurological Disorder Drugs Growth Trends by Region 2.2.1 Neurological Disorder Drugs Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Neurological Disorder Drugs Historic Market Size by Region (2017-2022) 2.2.3 Neurological Disorder Drugs Forecasted Market Size by Region (2023-2028) 2.3 Neurological Disorder Drugs Market Dynamics 2.3.1 Neurological Disorder Drugs Industry Trends 2.3.2 Neurological Disorder Drugs Market Drivers 2.3.3 Neurological Disorder Drugs Market Challenges 2.3.4 Neurological Disorder Drugs Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Neurological Disorder Drugs Players by Revenue 3.1.1 Global Top Neurological Disorder Drugs Players by Revenue (2017-2022) 3.1.2 Global Neurological Disorder Drugs Revenue Market Share by Players (2017-2022) 3.2 Global Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Neurological Disorder Drugs Revenue 3.4 Global Neurological Disorder Drugs Market Concentration Ratio 3.4.1 Global Neurological Disorder Drugs Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Neurological Disorder Drugs Revenue in 2021 3.5 Neurological Disorder Drugs Key Players Head office and Area Served 3.6 Key Players Neurological Disorder Drugs Product Solution and Service 3.7 Date of Enter into Neurological Disorder Drugs Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Neurological Disorder Drugs Breakdown Data by Type 4.1 Global Neurological Disorder Drugs Historic Market Size by Type (2017-2022) 4.2 Global Neurological Disorder Drugs Forecasted Market Size by Type (2023-2028) 5 Neurological Disorder Drugs Breakdown Data by Application 5.1 Global Neurological Disorder Drugs Historic Market Size by Application (2017-2022) 5.2 Global Neurological Disorder Drugs Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Neurological Disorder Drugs Market Size (2017-2028) 6.2 North America Neurological Disorder Drugs Market Size by Country (2017-2022) 6.3 North America Neurological Disorder Drugs Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Neurological Disorder Drugs Market Size (2017-2028) 7.2 Europe Neurological Disorder Drugs Market Size by Country (2017-2022) 7.3 Europe Neurological Disorder Drugs Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Neurological Disorder Drugs Market Size (2017-2028) 8.2 Asia-Pacific Neurological Disorder Drugs Market Size by Country (2017-2022) 8.3 Asia-Pacific Neurological Disorder Drugs Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Neurological Disorder Drugs Market Size (2017-2028) 9.2 Latin America Neurological Disorder Drugs Market Size by Country (2017-2022) 9.3 Latin America Neurological Disorder Drugs Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Neurological Disorder Drugs Market Size (2017-2028) 10.2 Middle East & Africa Neurological Disorder Drugs Market Size by Country (2017-2022) 10.3 Middle East & Africa Neurological Disorder Drugs Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 Novartis 11.1.1 Novartis Company Detail 11.1.2 Novartis Business Overview 11.1.3 Novartis Neurological Disorder Drugs Introduction 11.1.4 Novartis Revenue in Neurological Disorder Drugs Business (2017-2022) 11.1.5 Novartis Recent Development 11.2 GlaxoSmithKline 11.2.1 GlaxoSmithKline Company Detail 11.2.2 GlaxoSmithKline Business Overview 11.2.3 GlaxoSmithKline Neurological Disorder Drugs Introduction 11.2.4 GlaxoSmithKline Revenue in Neurological Disorder Drugs Business (2017-2022) 11.2.5 GlaxoSmithKline Recent Development 11.3 Merck & Co. 11.3.1 Merck & Co. Company Detail 11.3.2 Merck & Co. Business Overview 11.3.3 Merck & Co. Neurological Disorder Drugs Introduction 11.3.4 Merck & Co. Revenue in Neurological Disorder Drugs Business (2017-2022) 11.3.5 Merck & Co. Recent Development 11.4 Bayer 11.4.1 Bayer Company Detail 11.4.2 Bayer Business Overview 11.4.3 Bayer Neurological Disorder Drugs Introduction 11.4.4 Bayer Revenue in Neurological Disorder Drugs Business (2017-2022) 11.4.5 Bayer Recent Development 11.5 AstraZeneca 11.5.1 AstraZeneca Company Detail 11.5.2 AstraZeneca Business Overview 11.5.3 AstraZeneca Neurological Disorder Drugs Introduction 11.5.4 AstraZeneca Revenue in Neurological Disorder Drugs Business (2017-2022) 11.5.5 AstraZeneca Recent Development 11.6 Boehringer Ingelheim 11.6.1 Boehringer Ingelheim Company Detail 11.6.2 Boehringer Ingelheim Business Overview 11.6.3 Boehringer Ingelheim Neurological Disorder Drugs Introduction 11.6.4 Boehringer Ingelheim Revenue in Neurological Disorder Drugs Business (2017-2022) 11.6.5 Boehringer Ingelheim Recent Development 11.7 Teva Pharmaceutical 11.7.1 Teva Pharmaceutical Company Detail 11.7.2 Teva Pharmaceutical Business Overview 11.7.3 Teva Pharmaceutical Neurological Disorder Drugs Introduction 11.7.4 Teva Pharmaceutical Revenue in Neurological Disorder Drugs Business (2017-2022) 11.7.5 Teva Pharmaceutical Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details
List of Tables Table 1. Global Neurological Disorder Drugs Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Antipsychotic Table 3. Key Players of Hypnotic & Sedative Table 4. Key Players of Analgesics Table 5. Key Players of Anticoagulants Table 6. Key Players of Others Table 7. Global Neurological Disorder Drugs Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 8. Global Neurological Disorder Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 9. Global Neurological Disorder Drugs Market Size by Region (2017-2022) & (US$ Million) Table 10. Global Neurological Disorder Drugs Market Share by Region (2017-2022) Table 11. Global Neurological Disorder Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 12. Global Neurological Disorder Drugs Market Share by Region (2023-2028) Table 13. Neurological Disorder Drugs Market Trends Table 14. Neurological Disorder Drugs Market Drivers Table 15. Neurological Disorder Drugs Market Challenges Table 16. Neurological Disorder Drugs Market Restraints Table 17. Global Neurological Disorder Drugs Revenue by Players (2017-2022) & (US$ Million) Table 18. Global Neurological Disorder Drugs Market Share by Players (2017-2022) Table 19. Global Top Neurological Disorder Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurological Disorder Drugs as of 2021) Table 20. Ranking of Global Top Neurological Disorder Drugs Companies by Revenue (US$ Million) in 2021 Table 21. Global 5 Largest Players Market Share by Neurological Disorder Drugs Revenue (CR5 and HHI) & (2017-2022) Table 22. Key Players Headquarters and Area Served Table 23. Key Players Neurological Disorder Drugs Product Solution and Service Table 24. Date of Enter into Neurological Disorder Drugs Market Table 25. Mergers & Acquisitions, Expansion Plans Table 26. Global Neurological Disorder Drugs Market Size by Type (2017-2022) & (US$ Million) Table 27. Global Neurological Disorder Drugs Revenue Market Share by Type (2017-2022) Table 28. Global Neurological Disorder Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 29. Global Neurological Disorder Drugs Revenue Market Share by Type (2023-2028) Table 30. Global Neurological Disorder Drugs Market Size by Application (2017-2022) & (US$ Million) Table 31. Global Neurological Disorder Drugs Revenue Market Share by Application (2017-2022) Table 32. Global Neurological Disorder Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 33. Global Neurological Disorder Drugs Revenue Market Share by Application (2023-2028) Table 34. North America Neurological Disorder Drugs Market Size by Country (2017-2022) & (US$ Million) Table 35. North America Neurological Disorder Drugs Market Size by Country (2023-2028) & (US$ Million) Table 36. Europe Neurological Disorder Drugs Market Size by Country (2017-2022) & (US$ Million) Table 37. Europe Neurological Disorder Drugs Market Size by Country (2023-2028) & (US$ Million) Table 38. Asia-Pacific Neurological Disorder Drugs Market Size by Region (2017-2022) & (US$ Million) Table 39. Asia-Pacific Neurological Disorder Drugs Market Size by Region (2023-2028) & (US$ Million) Table 40. Latin America Neurological Disorder Drugs Market Size by Country (2017-2022) & (US$ Million) Table 41. Latin America Neurological Disorder Drugs Market Size by Country (2023-2028) & (US$ Million) Table 42. Middle East & Africa Neurological Disorder Drugs Market Size by Country (2017-2022) & (US$ Million) Table 43. Middle East & Africa Neurological Disorder Drugs Market Size by Country (2023-2028) & (US$ Million) Table 44. Novartis Company Detail Table 45. Novartis Business Overview Table 46. Novartis Neurological Disorder Drugs Product Table 47. Novartis Revenue in Neurological Disorder Drugs Business (2017-2022) & (US$ Million) Table 48. Novartis Recent Development Table 49. GlaxoSmithKline Company Detail Table 50. GlaxoSmithKline Business Overview Table 51. GlaxoSmithKline Neurological Disorder Drugs Product Table 52. GlaxoSmithKline Revenue in Neurological Disorder Drugs Business (2017-2022) & (US$ Million) Table 53. GlaxoSmithKline Recent Development Table 54. Merck & Co. Company Detail Table 55. Merck & Co. Business Overview Table 56. Merck & Co. Neurological Disorder Drugs Product Table 57. Merck & Co. Revenue in Neurological Disorder Drugs Business (2017-2022) & (US$ Million) Table 58. Merck & Co. Recent Development Table 59. Bayer Company Detail Table 60. Bayer Business Overview Table 61. Bayer Neurological Disorder Drugs Product Table 62. Bayer Revenue in Neurological Disorder Drugs Business (2017-2022) & (US$ Million) Table 63. Bayer Recent Development Table 64. AstraZeneca Company Detail Table 65. AstraZeneca Business Overview Table 66. AstraZeneca Neurological Disorder Drugs Product Table 67. AstraZeneca Revenue in Neurological Disorder Drugs Business (2017-2022) & (US$ Million) Table 68. AstraZeneca Recent Development Table 69. Boehringer Ingelheim Company Detail Table 70. Boehringer Ingelheim Business Overview Table 71. Boehringer Ingelheim Neurological Disorder Drugs Product Table 72. Boehringer Ingelheim Revenue in Neurological Disorder Drugs Business (2017-2022) & (US$ Million) Table 73. Boehringer Ingelheim Recent Development Table 74. Teva Pharmaceutical Company Detail Table 75. Teva Pharmaceutical Business Overview Table 76. Teva Pharmaceutical Neurological Disorder Drugs Product Table 77. Teva Pharmaceutical Revenue in Neurological Disorder Drugs Business (2017-2022) & (US$ Million) Table 78. Teva Pharmaceutical Recent Development Table 79. Research Programs/Design for This Report Table 80. Key Data Information from Secondary Sources Table 81. Key Data Information from Primary Sources List of Figures Figure 1. Global Neurological Disorder Drugs Market Share by Type: 2021 VS 2028 Figure 2. Antipsychotic Features Figure 3. Hypnotic & Sedative Features Figure 4. Analgesics Features Figure 5. Anticoagulants Features Figure 6. Others Features Figure 7. Global Neurological Disorder Drugs Market Share by Application in 2021 & 2028 Figure 8. Hospital Case Studies Figure 9. Clinic Case Studies Figure 10. Neurological Disorder Drugs Report Years Considered Figure 11. Global Neurological Disorder Drugs Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 12. Global Neurological Disorder Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 13. Global Neurological Disorder Drugs Market Share by Region: 2021 VS 2028 Figure 14. Global Neurological Disorder Drugs Market Share by Players in 2021 Figure 15. Global Top Neurological Disorder Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurological Disorder Drugs as of 2021) Figure 16. The Top 10 and 5 Players Market Share by Neurological Disorder Drugs Revenue in 2021 Figure 17. North America Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 18. North America Neurological Disorder Drugs Market Share by Country (2017-2028) Figure 19. United States Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 20. Canada Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. Europe Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Europe Neurological Disorder Drugs Market Share by Country (2017-2028) Figure 23. Germany Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 24. France Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. U.K. Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. Italy Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. Russia Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. Nordic Countries Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Asia-Pacific Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Asia-Pacific Neurological Disorder Drugs Market Share by Region (2017-2028) Figure 31. China Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Japan Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. South Korea Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. Southeast Asia Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. India Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. Australia Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Latin America Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Latin America Neurological Disorder Drugs Market Share by Country (2017-2028) Figure 39. Mexico Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Brazil Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Middle East & Africa Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Middle East & Africa Neurological Disorder Drugs Market Share by Country (2017-2028) Figure 43. Turkey Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 44. Saudi Arabia Neurological Disorder Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 45. Novartis Revenue Growth Rate in Neurological Disorder Drugs Business (2017-2022) Figure 46. GlaxoSmithKline Revenue Growth Rate in Neurological Disorder Drugs Business (2017-2022) Figure 47. Merck & Co. Revenue Growth Rate in Neurological Disorder Drugs Business (2017-2022) Figure 48. Bayer Revenue Growth Rate in Neurological Disorder Drugs Business (2017-2022) Figure 49. AstraZeneca Revenue Growth Rate in Neurological Disorder Drugs Business (2017-2022) Figure 50. Boehringer Ingelheim Revenue Growth Rate in Neurological Disorder Drugs Business (2017-2022) Figure 51. Teva Pharmaceutical Revenue Growth Rate in Neurological Disorder Drugs Business (2017-2022) Figure 52. Bottom-up and Top-down Approaches for This Report Figure 53. Data Triangulation Figure 54. Key Executives Interviewed
Novartis GlaxoSmithKline Merck & Co. Bayer AstraZeneca Boehringer Ingelheim Teva Pharmaceutical
The research report includes specific segments by region (country), by manufacturers, by Type and ... Read More
The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More
The research report includes specific segments by region (country), by manufacturers, by Type and ... Read More
The research report includes specific segments by region (country), by manufacturers, by Type and ... Read More